TriangleNCT02535247 · OUTCOME
Determine Overall Response Rate by 4 Cycles of Combination of Pembrolizumab and Copanlisib
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- 6 months
Analysis population: Study did not progress to portion with combination of pembrolizumab and copanlisib
Groups in this outcome
Treatment
MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles MK-3475
Combination
MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study MK-3475 Copanlisib
| Group | Source count |
|---|---|
| Treatment | 0 |
| Combination | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- units
- Participants
- groups
- description
- MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles MK-3475
- id
- OG000
- title
- Treatment
- description
- MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study MK-3475 Copanlisib
- id
- OG001
- title
- Combination
- population Description
- Study did not progress to portion with combination of pembrolizumab and copanlisib
- reporting Status
- POSTED
- time Frame
- 6 months
- title
- Determine Overall Response Rate by 4 Cycles of Combination of Pembrolizumab and Copanlisib
- type
- PRIMARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice